製品の概要

  • 製品名Anti-KRAS antibody
    KRAS 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to KRAS
  • アプリケーション適用あり: ICC/IF, WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Horse, Chicken, Dog, Pig
  • 免疫原

    Synthetic peptide conjugated to KLH derived from within residues 100 to the C-terminus of Human KRAS.

  • ポジティブ・コントロール
    • This antibody gave a positive signal in both Human brain and Human brain membrane tissue lysates.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab102007 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ICC/IF Use a concentration of 1 µg/ml.
WB 1/250. Detects a band of approximately 22 kDa (predicted molecular weight: 22 kDa).

ターゲット情報

  • 機能Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • 関連疾患Defects in KRAS are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
    Defects in KRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.
    Defects in KRAS are the cause of Noonan syndrome type 3 (NS3) [MIM:609942]. Noonan syndrome (NS) [MIM:163950] is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. It is a genetically heterogeneous and relatively common syndrome, with an estimated incidence of 1 in 1000-2500 live births. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS3 inheritance is autosomal dominant.
    Defects in KRAS are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
    Note=Defects in KRAS are a cause of pylocytic astrocytoma (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors.
    Defects in KRAS are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    Note=KRAS mutations are involved in cancer development.
  • 配列類似性Belongs to the small GTPase superfamily. Ras family.
  • 細胞内局在Cell membrane.
  • Information by UniProt
  • 参照データベース
  • 別名
    • c Ki ras2 antibody
    • c Kirsten ras protein antibody
    • c-K-ras antibody
    • c-Ki-ras antibody
    • Cellular c Ki ras2 proto oncogene antibody
    • Cellular transforming proto oncogene antibody
    • CFC2 antibody
    • cK Ras antibody
    • GTPase KRas antibody
    • K RAS p21 protein antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-Ras 2 antibody
    • KI RAS antibody
    • Ki-Ras antibody
    • KIRSTEN MURINE SARCOMA VIRUS 2 antibody
    • Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog antibody
    • Kirsten rat sarcoma viral oncogene homolog antibody
    • KRAS antibody
    • KRAS proto oncogene, GTPase antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-terminally processed antibody
    • NS antibody
    • NS3 antibody
    • Oncogene KRAS2 antibody
    • p21ras antibody
    • PR310 c K ras oncogene antibody
    • PR310 cK ras oncogene antibody
    • RALD antibody
    • RASK_HUMAN antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    see all

Anti-KRAS antibody 画像

  • All lanes : Anti-KRAS antibody (ab102007) at 1/250 dilution

    Lane 1 : Human brain tissue lysate - total protein (ab29466)
    Lane 2 : Human brain normal tissue lysate - membrane extract (ab29456)

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 22 kDa
    Observed band size : 22 kDa
    Additional bands at : 37 kDa,42 kDa. We are unsure as to the identity of these extra bands.

    Exposure time : 20 minutes
  • ICC/IF image of ab102007 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab102007 at 1µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Anti-KRAS antibody (ab102007) 使用論文

This product has been referenced in:
  • Cogoi S  et al. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res 41:4049-64 (2013). WB ; Human . Read more (PubMed: 23471001) »

See 1 Publication for this product

Product Wall

Thank you for contacting regarding our anti- KRAS antibodies

I have been able to review the products on our catalog as requested. Unfortunately I have found significant homologies with other RAS proteins for each of these. These immunogen g...

Read More
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton-X100 in PBS
Username

Dr. Kirk McManus

Verified customer

投稿 Sep 03 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"